Drugs / HydroVax-001B WNV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06745921 | Feb 2025 → Oct 2026 expected | West Nile fever | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HydroVax-001B WNV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06745921 ↗ |
| Modality | Vaccine | “A vaccine to West Nile Virus (WNV) that is prepared by propagating naturally attenuated Kunjin strain of WNV on well characterized low-passage Vero cells.” NCT06745921 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06745921 ↗ |